Recursion (NASDAQ:RXRX) reported fourth-quarter 2025 revenue of $35.5 million on Wednesday, significantly exceeding analyst estimates of $24.6 million. The performance was driven by the timing of ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

The U.S. Senate negotiations over a crypto market structure bill — the industry's top goal in its policy lobbying — hasn't yet resolved several disagreements as the talks drift toward the holiday ...

The last time I wrote about Recursion Pharmaceuticals (RXRX), it was with respect to a Seeking Alpha article entitled "Recursion: CDK7 Differentiation Is Initially Paying Off." With respect to this ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

The Eclipse Foundation's Jakarta EE Working Group has released Jakarta EE 11, the latest version of its enterprise Java platform, marking a significant step in modernizing enterprise Java development ...

Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is an emerging clinical-stage biotech firm that uses AI, bioinformatics, experimental biology, and automation to industrialize drug discovery for various ...